Siemens Healthcare has announced that the Food and Drug Administration (FDA) recently cleared the features associated with the Biograph mCT positron emission tomography/computed tomography (PET/CT) scanner. The Biograph mCT enables precise measurement of metabolic processes and data quantification, including the assessment of neurological disease and cancerous tissue, as well as cardiac blood flow (perfusion). Technological innovations and intelligent software solutions within the PET/CT result in accurate, consistent quantitative assessments.
Accuracy and reproducibility in PET quantification enable the physician to more precisely characterize cancer lesions, which permits better staging and monitoring of changes in activity over time for more accurate assessment of treatment response. The ability to measure absolute myocardial blood flow in cardiology allows the physician to more accurately assess multi-vessel disease. In neurology, noninvasive assessment of the brain can potentially improve the diagnosis and management of patients who present with signs of dementia.
Siemens implemented these clinical requirements in the Biograph mCT, which supports physicians in treating many neurological, oncological and cardiological diseases – through earlier, more precise diagnosis, as well as in therapy planning and precise monitoring of disease progression. With this additional information, physicians are better equipped to make decisions with high certainty and initiate more patient-tailored therapies.
The latest Biograph mCT can provide additional information to aid in the diagnosis of dementia, which affects an estimated 35.6 million people worldwide and may affect as many as 115.4 million people by 2050. Alzheimer’s disease is the most frequently diagnosed form of dementia.
Date: February 15, 2012
Source: Siemens Healthcare